These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 19338833)

  • 1. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection.
    Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Niforos F; Malet T; Santini J
    Aesthet Surg J; 2005; 25(4):365-75. PubMed ID: 19338833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
    Ascher B; Zakine B; Kestemont P; Baspeyras M; Bougara A; Santini J
    J Am Acad Dermatol; 2004 Aug; 51(2):223-33. PubMed ID: 15280841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview.
    Rzany B; Ascher B; Monheit G
    J Eur Acad Dermatol Venereol; 2010 Jan; 24 Suppl 1():1-14. PubMed ID: 19930409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient satisfaction after the treatment of glabellar lines with Botulinum toxin type A (Speywood Unit): a multi-centre European observational study.
    Molina B; Grangier Y; Mole B; Ribe N; Martín Diaz L; Prager W; Paliargues F; Kerrouche N
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1382-8. PubMed ID: 25495499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG; Dover J; Glogau RG; Goldberg DJ; Goldman MP; Schlessinger J
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines.
    Carruthers A; Carruthers J; Flynn TC; Leong MS
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S60-8. PubMed ID: 17241416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
    Monheit G; Carruthers A; Brandt F; Rand R
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
    Fagien S; Cox SE; Finn JC; Werschler WP; Kowalski JW
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S2-9. PubMed ID: 17241410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum type A toxin complex for the relief of upper back myofascial pain syndrome: how do fixed-location injections compare with trigger point-focused injections?
    Benecke R; Heinze A; Reichel G; Hefter H; Göbel H;
    Pain Med; 2011 Nov; 12(11):1607-14. PubMed ID: 21692970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine.
    Saper JR; Mathew NT; Loder EW; DeGryse R; VanDenburgh AM;
    Pain Med; 2007 Sep; 8(6):478-85. PubMed ID: 17716321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.